Skip to main content
. 2019 Mar 22;17(5):4013–4022. doi: 10.3892/etm.2019.7428

Table V.

Insulin levels at the end of the study.

Groups Median IQR Differences from 21th daya
Sham (n=9) 119.92 14.15 Z=2.301; P=0.021
PCOS control (n=9) 194.52 18.91 Z=0.059; P=0.953
Merformin (n=8) 106.64 53.97 Z=2.521; P=0.012
Metformin + PDE4i (n=10) 97.12 17.52 Z=2.803; P=0.005
a

Wilcoxon signed rank test results. PDE4i, phosphodiesterase 4 inhibitor; PCOS, polycystic ovary syndrome; IQR, interquartile range.